| Market cap | $92.83M |
|---|---|
| Enterprise value | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| Income | -$49.21 |
| Revenue Q/Q | 16.58% |
| Revenue Y/Y | 10.25% |
| P/E | 0.00 |
|---|---|
| Forward P/E | -21.67 |
| EV/Sales | 1.59 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | 1.20 |
| P/FCF | N/A |
| Price/Book | 8.86 |
| Book/Share | 0.16 |
| Cash/Share | N/A |
| FCF yield | -13.84% |
| Volume | 29.364k / 14.881k |
|---|---|
| Relative vol. | 1.97 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | -20.00% |
| Est. EPS Q/Q | -40.00% |
| Profit margin | N/A |
|---|---|
| Oper. margin | -54.61% |
| Gross margin | N/A |
| EBIT margin | -54.61% |
| EBITDA margin | -1.61% |
| Ret. on assets | -46.97% |
|---|---|
| Ret. on equity | 11,033.41% |
| ROIC | -23.06% |
| ROCE | -197.87% |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | -70.44 |
| Current ratio | 1.05 |
| Quick ratio | 0.73 |
| Volatility | 5.89% |
|---|---|
| Beta | 2.54 |
| RSI | 55.43 |
|---|
| Insider ownership | 1.22% |
|---|---|
| Inst. ownership | 26.79% |
| Shares outst. | 45.981M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 0.09% |
| Short ratio | 0.55 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 10 Jul 2024 |
Saturday, 5 August 2023
|
|
| 10 Oversold Canadian Stocks To Buy | |
Wednesday, 19 July 2023
|
|
| Theratechnologies (TSE:TH investor five-year losses grow to 88% as the stock sheds CA$16m this past week | |
Saturday, 16 July 2022
|
|
| Theratechnologies investors are sitting on a loss of 62% if they invested five years ago | |
Monday, 28 June 2021
|
|
| Where Do Hedge Funds Stand On Theratechnologies Inc. ? | |
Monday, 12 April 2021
|
|
| Theratechnologies to Present at the Bloom Burton & Co. Healthcare Investor Conference - Yahoo Finance | |
Wednesday, 15 July 2020
|
|
| Theratechnologies Inc. Q2 2020 Earnings Call Transcript | |
Monday, 2 March 2020
|
|
| Change to Theratechnologies Management | |
Thursday, 27 February 2020
|
|
| Introducing Theratechnologies , The Stock That Soared 334% In The Last Five Years | |
Powered by
Robintrack.
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Christian Marsolais (57) Senior Vice President and Chief Medical Officer since 2016 | 57 | 2016 | $949,250 |
| Conor Walshe | 2019 | $701,880 | |
| Jovan Antunovic (50) Senior Vice President and Chief Commercial Office since 2018 | 50 | 2018 | $656,200 |
| Philippe Dubuc (53) Chief Financial Officer and Senior Vice President since 2019 | 53 | 2019 | $608,250 |
| Jocelyn Lafond (52) Vice President - Legal Affairs and Corporate Secretary | 52 | $444,164 | |
| Denis Boucher (54) Vice President - Communications and Corporate Affairs since 2018 | 54 | 2018 | $437,026 |
| Marie-Noel Colussi (51) Vice President - Finance since 2002 | 51 | 2002 | $223,683 |
| Dawn Svoronos (66) Independent Chairman of the Board since 2013 | 66 | 2013 | $213,000 |
| Dale Weil (64) Independent Director since 2017 | 64 | 2017 | |
| Alain Trudeau | 2020 | ||
| Paul Pommier (77) Independent Director since 2013 | 77 | 2013 | |
| Andrew Molson (52) Independent Director since 2020 | 52 | 2020 | |
| Gary Littlejohn (65) Independent Director since 2018 | 65 | 2018 | |
| Gerald Lacoste (76) Independent Director since 2006 | 76 | 2006 | |
| Sheila Frame (58) Independent Director since 2019 | 58 | 2019 | |
| Paul Levesque (56) President, Chief Executive Officer, and Director since 2020 | 56 | 2020 |
theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.
- Health Care > Drug Manufacturers—Specialty & Generic
- Theratechnologies Inc., 2015 Peel Street, Montreal H3A 1T8, Canada
- 514 336 7800
- Investor relations
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 30 Aug 2022 | 30 May 2022 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $23.416 | $13.2 | |||
| Short term investments | $13.046 | $19.291 | |||
| Net receivables | $11.53 | $12.853 | |||
| Inventory | $23.141 | $24.976 | |||
| Other current assets | $0.5 | $0.596 | |||
| Total current assets | $77.872 | $78.302 | |||
| Long term investments | |||||
| Property, plant & equipment | $3.175 | $2.919 | |||
| Goodwill | |||||
| Intangible assets | $12.849 | $13.491 | |||
| Other assets | $1.959 | $0.647 | |||
| Total assets | $95.855 | $95.359 | |||
| Current liabilities | |||||
| Accounts payable | $41.076 | $43.555 | |||
| Short long term debt | $26.645 | ||||
| Other current liabilities | $6.306 | $5.889 | |||
| Total current liabilities | $74.495 | $49.923 | |||
| Long term debt | $37.759 | $55.203 | |||
| Other liabilities | $0.1 | $0.108 | |||
| Minority interest | |||||
| Total liabilities | $113.915 | $107.003 | |||
| Stockholders' equity | |||||
| Common stock | $335.762 | $335.752 | |||
| Retained earnings | -$374.556 | -$367.007 | |||
| Treasury stock | $2.757 | $4.574 | |||
| Capital surplus | $17.977 | $15.037 | |||
| Total stockholder equity | -$18.06 | -$11.644 | |||
| Net tangible assets | -$30.909 | -$25.135 | |||
| (in millions USD) | 2021 | 2020 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $20.399 | $12.737 | ||
| Short term investments | $22.979 | $8.223 | ||
| Net receivables | $10.928 | $13.185 | ||
| Inventory | $29.141 | $25.145 | ||
| Other current assets | $0.74 | $0.52 | ||
| Total current assets | $91.908 | $64.807 | ||
| Long term investments | ||||
| Property, plant & equipment | $2.854 | $3.483 | ||
| Goodwill | ||||
| Intangible assets | $23.829 | $31.852 | ||
| Other assets | $0.621 | |||
| Total assets | $119.212 | $100.142 | ||
| Current liabilities | ||||
| Accounts payable | $15.526 | $17.51 | ||
| Short long term debt | ||||
| Other current liabilities | $4.237 | $6.679 | ||
| Total current liabilities | $45.076 | $41.919 | ||
| Long term debt | $54.227 | $52.403 | ||
| Other liabilities | $0.094 | $0.041 | ||
| Minority interest | ||||
| Total liabilities | $101.452 | $96.918 | ||
| Stockholders' equity | ||||
| Common stock | $335.752 | $287.312 | ||
| Retained earnings | -$335.248 | -$300.129 | ||
| Treasury stock | $4.413 | $3.976 | ||
| Capital surplus | $12.843 | $12.065 | ||
| Total stockholder equity | $17.76 | $3.224 | ||
| Net tangible assets | -$6.069 | -$28.628 | ||
Income statement
| (in millions USD) | 30 Aug 2022 | 30 May 2022 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $20.811 | $19.268 | |||
| Cost of revenue | $5.292 | $7.759 | |||
| Gross profit | $15.519 | $11.509 | |||
| Operating activities | |||||
| Research & development | $8.425 | $11.056 | |||
| Selling, general & administrative | $12.613 | $20.194 | |||
| Total operating expenses | $26.33 | $40.229 | |||
| Operating income | -$5.519 | -$20.961 | |||
| Income from continuing operations | |||||
| Net other income | -$1.879 | -$1.644 | |||
| EBIT | -$5.519 | -$20.961 | |||
| Income before tax | -$7.398 | -$22.605 | |||
| Income tax expense | $0.151 | $0.122 | |||
| Minority interest | |||||
| Net income | |||||
| Net income | -$7.549 | -$22.727 | |||
| Income (for common shares) | -$7.549 | -$22.727 | |||
| (in millions USD) | 2021 | 2020 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $69.823 | $66.053 | ||
| Cost of revenue | $18.378 | $22.021 | ||
| Gross profit | $51.445 | $44.032 | ||
| Operating activities | ||||
| Research & development | $28.274 | $18.019 | ||
| Selling, general & administrative | $43.525 | $39.089 | ||
| Total operating expenses | $95.059 | $84.01 | ||
| Operating income | -$25.236 | -$17.957 | ||
| Income from continuing operations | ||||
| Net other income | -$6.426 | -$4.694 | ||
| EBIT | -$25.236 | -$17.957 | ||
| Income before tax | -$31.662 | -$22.651 | ||
| Income tax expense | $0.063 | $0.016 | ||
| Minority interest | ||||
| Net income | ||||
| Net income | -$31.725 | -$22.667 | ||
| Income (for common shares) | -$31.725 | -$22.667 | ||
Cash flows
| (in millions USD) | 30 Aug 2022 | 30 May 2022 | |||
|---|---|---|---|---|---|
| Net income | -$7.549 | -$22.727 | |||
| Operating activities | |||||
| Depreciation | $0.856 | $8.491 | |||
| Change in accounts receivable | $1.059 | $1.077 | |||
| Changes in inventory | $1.536 | $0.76 | |||
| Total cash flows from operations | -$1.196 | -$1.147 | |||
| Investing activities | |||||
| Capital expenditures | -$0.615 | -$0.305 | |||
| Investments | $5.68 | $0.402 | |||
| Other cash flows from investing | $0.092 | $0.103 | |||
| Total cash flows from investing | $5.157 | $0.2 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Net borrowings | $11.104 | -$0.154 | |||
| Other cash flows from financing | -$4.761 | -$0.03 | |||
| Total cash flows from financing | $6.348 | -$0.184 | |||
| Effect of exchange rate | -$0.093 | -$0.011 | |||
| Change in cash and equivalents | $10.216 | -$1.142 | |||
| (in millions USD) | 2021 | 2020 | ||
|---|---|---|---|---|
| Net income | -$31.725 | -$22.667 | ||
| Operating activities | ||||
| Depreciation | $8.748 | $8.52 | ||
| Change in accounts receivable | $1.852 | -$2.253 | ||
| Changes in inventory | -$4.187 | -$4.872 | ||
| Total cash flows from operations | -$14.477 | -$13.554 | ||
| Investing activities | ||||
| Capital expenditures | -$0.127 | -$0.032 | ||
| Investments | -$12.116 | $4.447 | ||
| Other cash flows from investing | -$0.172 | $0.361 | ||
| Total cash flows from investing | -$12.454 | $4.776 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Net borrowings | -$5.635 | -$4.068 | ||
| Other cash flows from financing | -$7.147 | -$3.306 | ||
| Total cash flows from financing | $34.557 | -$7.229 | ||
| Effect of exchange rate | $0.036 | $0.083 | ||
| Change in cash and equivalents | $7.662 | -$15.924 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Mai Capital Management |
-75.00%
|
29,242 | $48,542 |
| 2024 Q1 | Federation Des Caisses Desjardins Du Quebec |
Opened
|
44,556 | $94,532 |
| 2024 Q1 | Summit Trail Advisors |
Opened
|
33,090 | $54,929 |
| 2024 Q1 | Bank Of Montreal can/ |
-60.52%
|
18,262 | $27,111 |
| 2024 Q1 | Northern Trust Corp |
Opened
|
12,861 | $21,349 |
| 2024 Q1 | Pnc Services |
-54.01%
|
10,000 | $16,600 |
| 2024 Q1 | Modern Wealth Management |
Opened
|
10,500 | $12,810 |
| 2024 Q1 | Morgan Stanley |
-0.32%
|
2,252,232 | $3,738,705 |
| 2024 Q1 | Newedge Advisors |
+560.00%
|
8,250 | $13,695 |
| 2024 Q1 | Aigh Capital Management |
+0.16%
|
3,725,204 | $6,156,598 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Soleus Capital Management, L.P. | 10.44% | 4,801,376 | |
| Aigh Capital Management | 8.10% | 3,725,204 | |
| Nantahala Capital Management | 5.83% | 2,682,228 | |
| Morgan Stanley | 4.90% | 2,252,232 | |
| Worth Venture Partners | 1.97% | 906,557 | |
| National Bank Of Canada fi/ | 1.37% | 631,912 | |
| Cyndeo Wealth Partners | 1.13% | 520,604 | |
| Cibc World Market Inc | 0.91% | 417,590 | |
| Osaic Holdings, Inc | 0.28% | 128,054 | |
| Creative Financial Designs Inc adv | 0.21% | 98,019 |
Sign up